NY-FUNDGUARD
25.3.2024 13:01:34 CET | Business Wire | Press release
FundGuard, the industry’s first fully cloud-native, AI-powered, multi-asset class investment accounting platform for asset managers, asset owners, custodian banks and fund administrators today announced the successful closure of its Series C funding round, amounting to $100 million. This latest round of investment - led by Key1 Capital and new investors including Euclidean Capital and funds managed by Hamilton Lane (Nasdaq: HLNE) - marks another significant milestone on FundGuard’s path towards becoming the industry’s new era investment accounting utility.
The round also saw strong participation from existing strategic investors, plus the company’s earliest financial investors: Blumberg Capital and Team8.
Founded in 2018, FundGuard is transforming investment operations by leveraging cloud-native technology and AI capabilities to modernize and streamline investment accounting operations and workflows. Key to the company’s success has been the combined expertise of its leadership, including experienced funds industry executives and enterprise cloud technology and data science innovators. Backed by some of the world’s leading financial institutions and now with a total investment of over $150 million to date, this round follows two years of evolution and expansion, including new client acquisition, customer onboarding, significant hiring of top talent across Customer Success, R&D, Product Management and Sales, and the opening of the company’s Boston, London and Toronto offices.
“FundGuard is shaping the future of investment and fund accounting,” said Lior Yogev, CEO and Co-Founder, FundGuard. “This latest significant investment round reflects the ongoing support of the industry, the confidence our investors have in the value our products bring to the market, and their trust in our leadership and strategic roadmap.”
“The exceptional team at FundGuard has developed a unique, cutting-edge technology platform over the last five years, empowering asset managers and fund administrators with a timely, accurate, and cost-efficient solution to support their investment accounting operations,” said Amit Pilowsky, Co-Founder and Managing Partner, Key1 Capital. “It is rare to witness a company at this stage receiving significant attention from the largest and most sophisticated clients in an industry dominated by incumbents. This serves as a testament to just how valuable and unique FundGuard’s solution is. FundGuard is just scratching the surface of its potential to revolutionize the Investment Management industry, and we are honored to be their partner.”
The funds raised in this round will be strategically deployed by FundGuard for ongoing investment in product innovation and continued onboarding of existing and new customers.
“We are thrilled to partner with our newest investors,” said John Lehner, President, FundGuard. “With their support and partnership, and the continued dedication of our existing investors and talented team, FundGuard is poised for continued growth and market expansion.”
About FundGuard
FundGuard is a cloud-native SaaS platform for investment management and administration that is powered by AI. FundGuard helps asset managers and their service providers to manage mutual funds, ETFs, hedge funds, insurance products, and pension funds, supporting digital transformation, operations automation, AI-based insights, resiliency, and migration to the cloud. FundGuard is backed by strategic partners including Citi and State Street, and investment firms Blumberg Capital, Key1 Capital, LionBird Ventures, and Team8 among others.
Please visit www.fundguard.com
About Key1 Capital
Key1 Capital is a growth-stage VC fund backing Israeli and European companies. With two decades of experience in leadership roles at Goldman Sachs, the team has played a key role in the growth of top-tier technology companies scaling globally. Key1 actively seeks to partner with visionary founders who think big and are driven by strong values, helping them meaningfully expand through ultimate exit.
Please visit: www.key1capital.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325557613/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Amazfit Announces the T-Rex Ultra 2: a Titanium GPS Watch Engineered for the Extreme19.2.2026 13:00:00 CET | Press release
With preloaded global maps, intelligent route tools, and weeks-long battery life, the T-Rex Ultra 2 is made for those who seek boundaries only to push beyond Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the T-Rex Ultra 2, the latest and most advanced member of its rugged T-Rex lineup. As part of the T-Rex family, the T-Rex Ultra 2 is built for uncertainty—designed to remain reliable in conditions where plans, environments, and outcomes are never fully defined. Purpose-built for extreme environments, the T-Rex Ultra 2 combines premium materials, enhanced navigation capabilities, and extended battery life to support athletes and explorers tackling long, complex routes where preparation and reliability matter most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219679075/en/ Amazfit Announces the T-Rex Ultra 2: a Titanium GPS Watch Engineered for the Extreme “With the T-Rex Ultra 2, we
YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency19.2.2026 12:00:00 CET | Press release
Single dose of YOLT-202 led to rapid, robust and dose-dependent increases in AAT levels to normal rangeSingle dose of YOLT-202 was well tolerated with a favorable safety profile YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene editing therapies, today announced positive interim data from an investigator-initiated trial (IIT) of YOLT-202, the Company’s investigational in vivo base editing therapy, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) that demonstrated positive safety and tolerability as well as meaningful increases in AAT levels in evaluated patients treated with the 35 mg and 45 mg dose levels. “These interim findings mark an exciting and important milestone for YolTech and for patients living with severe AATD. The rapid, robust, and dose‑dependent increases in functional AAT levels observed in this study—particularly among individuals with the PiZZ genotype—underscore the transformative potential of in vivo base editing as
Infobip Recognized as RCS for Business Leader by Juniper Research19.2.2026 11:15:00 CET | Press release
Recognition comes as Infobip celebrates its 20th anniversary Global cloud communications platform Infobip has been named the number one Established Leader in the Juniper Research RCS for Business 2026 Leaderboard. The analyst firm scored Infobip as the top vendor out of 17 because of its superior capability and capacity, enhanced product and position and significant market presence. Juniper Research scores vendors on a range of factors including but not limited to their geographical reach, depth of partnerships, RCS value-added services, notable RCS deployments, and innovation. According to Juniper Research, Infobip stands out for its wide network of mobile operator connections for RCS for Business and its extensive geographic reach, including being the first provider to launch RCS messaging across all major US telecom carriers. Brands such as Virgin Atlantic are using Infobip’s RCS solutions to deliver interactive, conversational messaging that drives stronger customer engagement. Mol
Serviceplan Group Deploys Creative AI Across Global Operations in Partnership With Luma AI19.2.2026 11:00:00 CET | Press release
Serviceplan Group becomes the first of the world’s largest agency groups to standardize AI for creative work across professional workflows at scale, strengthening productivity and long-term competitiveness. Serviceplan Group today announced a strategic partnership with Luma AI to deploy AI for creative work across the agency group’s global operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219346568/en/ Serviceplan Group today announced a strategic partnership with Luma AI to deploy AI for creative work across the agency group’s global operations. Shown here (L-R) Alex Schill, Global Chief Creative Officer of Serviceplan Group, Jason Day, Head of EMEA for Luma AI, Amit Jain, Co-Founder and CEO of Luma AI, and Florian Haller, CEO of Serviceplan Group. Under the agreement, Luma AI will serve as Serviceplan Group’s AI technology partner, embedding AI for creative work into professional workflows spanning strategy, cr
GekkoVet and Royal Canin Enter Latin America with Mexico Launch, Opening a New Continent in their Global Partnership19.2.2026 10:59:00 CET | Press release
GekkoVet, the Finnish leader in AI-powered clinical decision support for veterinarians, and Royal Canin, a global pioneer in pet health through nutrition, announce the launch of their strategic collaboration in Mexico. This marks the first national rollout of their partnership in Latin America, expanding the initiative that began earlier this year with successful deployments in Asia. Royal Canin Mexico is equipping veterinary teams with GekkoVet’s intelligent platform, which provides real-time diagnostic assistance, treatment recommendations, and drug information. The collaboration aims to enhance clinical efficiency, improve patient outcomes, and support veterinarians with evidence-based tools that integrate seamlessly into daily practice. “This launch in Mexico is a major step forward—not just regionally, but globally,” said Johanna Majamaa, DVM and co-founder of GekkoVet. “After strong momentum in Asia, entering Latin America opens a new chapter in our mission to empower veterinaria
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom